Drugs that contain Ceritinib

1. List of Zykadia drug patents

ZYKADIA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8188276 NOVARTIS 2,4-pyrimidinediamine compounds and their uses
Jan, 2023

(2 months ago)

US8835430 NOVARTIS 2,4-pyrimidinediamine compounds and their uses
Jan, 2023

(2 months ago)

US9416112 NOVARTIS 2,4-pyrimidinediamine compounds and their uses
Jan, 2023

(2 months ago)

US9018204 NOVARTIS 2,4-pyrimidinediamine compounds and their uses
Jan, 2023

(2 months ago)

US7893074 NOVARTIS 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
Apr, 2026

(3 years from now)

US8399450 NOVARTIS Compounds and compositions as protein kinase inhibitors
Nov, 2027

(4 years from now)

US7964592 NOVARTIS 2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
Apr, 2028

(5 years from now)

US8039479 NOVARTIS Compounds and compositions as protein kinase inhibitors
Jun, 2030

(7 years from now)

US9309229 NOVARTIS Crystalline forms of 5-chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine
Jan, 2032

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8377921 NOVARTIS Compounds and compositions as protein kinase inhibitors
Nov, 2027

(4 years from now)

US8703787 NOVARTIS Methods of using ALK inhibitors
Feb, 2032

(8 years from now)

Exclusivity Exclusivity Expiration
ODE* (ODE*) May 26, 2024

Market Authorisation Date: 18 March, 2019

Treatment: Treatment of a cancer mediated by an anaplastic lymphoma kinase (alk)

Dosage: TABLET;ORAL

More Information on Dosage

ZYKADIA family patents

87

United States

20

China

20

European Union

14

Spain

13

Australia

13

Japan

12

Brazil

12

Korea, Republic of

10

Denmark

10

Slovenia

10

Portugal

10

Cyprus

10

Poland

9

Mexico

9

Russia

8

Hong Kong

8

Argentina

8

Croatia

8

Canada

7

South Africa

7

Norway

7

Taiwan, Province of China

7

New Zealand

6

Israel

5

Singapore

5

Ecuador

EA

5

EA

4

Austria

4

Morocco

4

Malaysia

4

Peru

4

RS

4

Tunisia

3

Lithuania

3

Hungary

3

Colombia

3

Iceland

3

San Marino

3

Chile

3

United Kingdom

3

Ukraine

2

Jordan

2

Germany

2

Guatemala

YU

2

Yugoslavia

2

Georgia

2

ME

1

El Salvador

1

Cuba

1

Costa Rica

1

Honduras

1

Sweden

1

Netherlands

1

Dominican Republic

1

Luxembourg

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic